- Report
- August 2022
- 120 Pages
Global
From €3119EUR$3,500USD£2,705GBP
- Report
- January 2025
- 132 Pages
Global
From €847EUR$950USD£734GBP
- Report
- December 2023
- 132 Pages
Global
From €847EUR$950USD£734GBP
- Report
- November 2021
- 747 Pages
Global
From €3564EUR$4,000USD£3,091GBP
- Report
- November 2021
- 620 Pages
Global
From €3564EUR$4,000USD£3,091GBP
- Book
- March 2024
- 496 Pages
- Book
- June 2022
- 496 Pages
- Book
- November 2019
- 368 Pages
- Book
- June 2019
- 304 Pages
- Book
- June 2019
- 496 Pages
- Book
- April 2018
- 312 Pages
- Book
- January 2016
- 472 Pages
- Book
- January 2015
- 600 Pages
- Book
- October 2009
- 912 Pages
- Book
- July 2024
- 250 Pages

The Antibody Drug market is a subset of the biotechnology industry that focuses on the development and commercialization of therapeutic antibodies. Antibody drugs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These drugs are designed to target specific molecules in the body, such as proteins, hormones, and enzymes, and can be used to block or activate certain pathways. Antibody drugs are typically administered intravenously or subcutaneously, and can be used in combination with other drugs or therapies.
The Antibody Drug market is highly competitive, with many companies investing in research and development to create new and improved treatments. Companies in the market are focused on developing novel antibodies, as well as improving existing treatments. Additionally, companies are investing in the development of biosimilars, which are generic versions of existing antibody drugs.
Some companies in the Antibody Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi. Show Less Read more